170 related articles for article (PubMed ID: 12352398)
1. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
Thalmann GN; Markwalder R; Walter B; Studer UE
J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
[TBL] [Abstract][Full Text] [Related]
2. Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort.
Somiya S; Kobori G; Ito K; Nakagawa H; Takahashi T; Koterazawa S; Takaoka N; Haitani T; Nagahama K; Ito M; Megumi Y; Higashi Y; Moroi S; Akao T; Yamada H; Kanno T
Int J Urol; 2023 Oct; 30(10):853-858. PubMed ID: 37278493
[TBL] [Abstract][Full Text] [Related]
3. Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guérin for the treatment of upper tract carcinoma in situ.
McElree IM; Mott SL; Hougen HY; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jul; 42(7):221.e9-221.e16. PubMed ID: 38609747
[TBL] [Abstract][Full Text] [Related]
4. The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome.
Lima W; Wang Y; Miyamoto H
Urol Oncol; 2023 Aug; 41(8):357.e1-357.e9. PubMed ID: 37142451
[TBL] [Abstract][Full Text] [Related]
5. Successful Kidney-Sparing Systemic Therapy for a High-Risk Ureteral Carcinoma Case.
Yuan P; Li X; Yuan Y; Xu P; Wang H
Urol Int; 2023; 107(9):895-898. PubMed ID: 37748442
[TBL] [Abstract][Full Text] [Related]
6. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma.
Mandalapu RS; Remzi M; de Reijke TM; Margulis V; Palou J; Kapoor A; Yossepowitch O; Coleman J; Traxer O; Anderson JK; Catto J; de la Rosette J; O'Brien T; Zlotta A; Matin SF
World J Urol; 2017 Mar; 35(3):355-365. PubMed ID: 27233780
[TBL] [Abstract][Full Text] [Related]
7. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Rose KM; Murray KS; Labbate C; Woldu S; Linehan J; Jacob J; Kaimakliotis H; Dickstein R; Feldman A; Matin SF; Lotan Y; Humphreys MR; Sexton WJ
Eur Urol Focus; 2023 Sep; 9(5):807-812. PubMed ID: 37059620
[TBL] [Abstract][Full Text] [Related]
8. Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma.
McElree IM; Belzer A; Mott SL; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jan; 42(1):20.e9-20.e15. PubMed ID: 37805338
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Labbate C; Woldu S; Murray K; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner B; Feldman A; Lotan Y; Matin SF
J Urol; 2023 May; 209(5):872-881. PubMed ID: 36657029
[TBL] [Abstract][Full Text] [Related]
10. Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
Luo HL
Int J Urol; 2024 Apr; 31(4):421. PubMed ID: 38567803
[No Abstract] [Full Text] [Related]
11. Comparison of intravesical chemotherapy regimens after radical nephroureterectomy for upper tract urothelial carcinoma and analysis of risk factors for postoperative recurrence.
Jiang SC; Liao YG; Luo J; Hu D; Wang YD; He K
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2387-2395. PubMed ID: 38567601
[TBL] [Abstract][Full Text] [Related]
12. Editorial Comment on Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
Taoka R; Sugimoto M
Int J Urol; 2024 Apr; 31(4):418-419. PubMed ID: 38299737
[No Abstract] [Full Text] [Related]
13. Letter to the Editor Re: Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
Urabe F
Int J Urol; 2024 Apr; 31(4):420. PubMed ID: 38287210
[No Abstract] [Full Text] [Related]
14. Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507).
Tempo J; Bolton D; O'Callaghan M
BMC Urol; 2023 Nov; 23(1):194. PubMed ID: 37996890
[TBL] [Abstract][Full Text] [Related]
15. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
Linehan J; Gottlieb J; Woldu SL; Labbate C; Rose K; Sexton W; Kaimakliotis H; Jacob J; Dickstein R; Nieder A; Bjurlin M; Humphreys M; Ghodoussipor S; Quek M; O'Donnell M; Eisner BH; Feldman AS; Matin SF; Lotan Y; Murray KS
Eur Urol Focus; 2023 Nov; 9(6):1052-1058. PubMed ID: 37263827
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
Civriz AH; Teke K; Akdas EM; Dillioglugil O; Vural C; Yaprak Bayrak B
Urol Oncol; 2023 Dec; 41(12):486.e1-486.e13. PubMed ID: 37690934
[TBL] [Abstract][Full Text] [Related]
17. Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
Rosen GH; Nallani A; Muzzey C; Murray KS
J Urol; 2022 Jun; 207(6):1302-1311. PubMed ID: 35130080
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients.
Morra S; Incesu RB; Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Creta M; Califano G; Collà Ruvolo C; Saad F; Shariat SF; Chun FKH; de Cobelli O; Musi G; Briganti A; Tilki D; Ahyai S; Carmignani L; Longo N; Karakiewicz PI
World J Urol; 2024 May; 42(1):343. PubMed ID: 38775841
[TBL] [Abstract][Full Text] [Related]
19. Myxoid Pseudotumor Changes Affecting the Distal Ureter Associated With Urothelial Carcinoma In Situ.
Ortiz-Rey JA; García-Baizán A; Bellas-Pereira A; Barciela-Bastos A; Gómez-de María C; Conde-Ferreirós M
Int J Surg Pathol; 2024 Jun; 32(4):772-775. PubMed ID: 37525552
[TBL] [Abstract][Full Text] [Related]
20. The Evolution of Upper Tract Urothelial Carcinoma Management in Kidney Recipients.
Lin KJ; Chen SY; Chiang YJ; Chu SH; Liu KL; Lin CT; Pan PY; Wang HH
Transplant Proc; 2024 Apr; 56(3):554-556. PubMed ID: 38670734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
